secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001140361-26-019430
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed Q1 revenue $306M, BRINSUPRI $207.9M (44% QoQ); reiterates FY guidance
----------------------------------------------------------------------------

- Total Q1 2026 revenue $306.0M vs $92.8M YoY; BRINSUPRI contributed $207.9M (+44% vs Q4 2025).
- Net loss narrowed to $163.6M ($0.76/sh) from $256.6M ($1.42/sh); cash & securities $1.2B.
- FY 2026 guidance reaffirmed: BRINSUPRI revenue >=$1B, ARIKAYCE $450-470M.
- Phase 3b ENCORE (ARIKAYCE in MAC) met primary and all multiplicity-controlled endpoints; sNDA H2 2026.
- BRINSUPRI received UK marketing authorization; Phase 3 TPIP PAH study initiated in April 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036126019430/0001140361-26-019430-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036126019430/ef20072589_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-019430

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer